Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowheadâs RNAi-based therapeutics leverage this natural pathway of gene silencing. Source
No articles found.
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into ...
Sangamo Therapeutics, Inc. is focused on transl...
Akers Biosciences, Inc. (aka Akers Bio) was founded in 1989, with the objective of...
Akers Biosciences, Inc. (aka Akers Bio) was fou...
Prevail Therapeutics is applying precision medicine to the development of gene the...
Prevail Therapeutics is applying precision medi...
Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company. We ...
Corvus Pharmaceuticals is a clinical science-dr...
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indicatio...
Kamada Ltd. is focused on plasma-derived protei...
Join the National Investor Network and get the latest information with your interests in mind.